Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262248 | 0.83 | NPC1 (0.48) | NPC1RAB9ALMNAHTTPOLB | |
| SCHEMBL8385469 | 0.80 | NPC1 (0.61) | NPC1RAB9AKDM4CLMNAHTT | |
| SCHEMBL20827561 | 0.77 | NPC1 (0.61) | NPC1RAB9AKDM4CLMNAHTT | |
| SCHEMBL11235509 | 0.76 | TAAR1 (0.58) | NPC1RAB9AKDM4CTAAR1POLB | |
| SCHEMBL9830276 | 0.76 | NLRP3 (0.48) | NPC1RAB9AMEN1KMT2AS1PR1 | |
| Acetic Acid SCHEMBL11587316 | 0.75 | NPSR1 (0.49) | NPC1RAB9AHTTMEN1KMT2A | |
| SCHEMBL11922803 | 0.75 | CHRM2 (0.47) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL1520513 | 0.75 | NPC1 (0.59) | NPC1RAB9AKDM4CLMNAHTT | |
| SCHEMBL14397866 | 0.73 | TAAR1 (0.55) | NPC1RAB9ATAAR1 | |
| SCHEMBL30787471 | 0.73 | NPC1 (0.57) | NPC1RAB9AKDM4CLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | XDH, PNP, MAVS | NPC1 347/4885RAB9A 3122/4885KDM4C 1817/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | NPC1 347/4885RAB9A 3122/4885KDM4C 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.